Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial
Key Points. Independent prognostic impact of biological markers, notably TP53 and SF3B1 mutations, in CLL patients requiring therapy.NOTCH1 mutation as a predictive factor for reducedbenefit from the addition ofrituximab to FC chemotherapy.
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
March 20, 2014
|
| In: |
Blood
Year: 2014, Volume: 123, Issue: 21, Pages: 3247-3254 |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2014-01-546150 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood-2014-01-546150 Verlag, lizenzpflichtig, Volltext: https://ashpublications.org/blood/article/123/21/3247/32778/Gene-mutations-and-treatment-outcome-in-chronic |
| Author Notes: | Stephan Stilgenbauer, Andrea Schnaiter, Peter Paschka, Thorsten Zenz, Marianna Rossi, Konstanze Döhner, Andreas Bühler, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Dirk Winkler, Eugen Tausch, Patrick Hoth, Jennifer Edelmann, Daniel Mertens, Lars Bullinger, Manuela Bergmann, Sabrina Kless, Silja Mack, Ulrich Jäger, Nancy Patten, Lin Wu, Michael K. Wenger, Günter Fingerle-Rowson, Peter Lichter, Mario Cazzola, Clemens M. Wendtner, Anna M. Fink, Kirsten Fischer, Raymonde Busch, Michael Hallek, and Hartmut Döhner |
| Summary: | Key Points. Independent prognostic impact of biological markers, notably TP53 and SF3B1 mutations, in CLL patients requiring therapy.NOTCH1 mutation as a predictive factor for reducedbenefit from the addition ofrituximab to FC chemotherapy. |
|---|---|
| Item Description: | Gesehen am 17.08.2020 |
| Physical Description: | Online Resource |
| ISSN: | 1528-0020 |
| DOI: | 10.1182/blood-2014-01-546150 |